A new study may have found a potentially easier, less disruptive and more effective way to treat the second leading cause of ...

BioProtect’s lead product is a spacer system designed to protect healthy tissues during radiation therapies for prostate ...

Ceramides-lipid molecules in cells that affect many physiological functions including cell differentiation, migration, and ...

CHICAGO -- Patients with advanced prostate cancer treated with enzalutamide (Xtandi) had a significantly greater decline in ...

Prostate-specific antigen (PSA) blood testing likely reduces the risk of death from prostate cancer, found a new review ...

Editor's note: Dr. Jamin Brahmbhatt is a urologist and robotic surgeon with Orlando Health and an assistant professor at the University of Central Florida’s College of Medicine.When I learned that ...

Approximately one in eight American men will be diagnosed with prostate cancer during their lifetime. For most of them, if ...

Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.

Testosterone replacement therapy improved function without PSA recurrence in prostate cancer survivors with hypogonadism.